Losartan
Drug Category | Drug | IHD Dosing | Administration Timing Around HD Session |
---|---|---|---|
Angiotensin II Receptor Blockers | Losartan | 50-100mg PO Q24H | Administer Anytime During HD; Post HD if Hypotensive |
Molecular Weight (Da) | Excreted Unchanged (%) | Normal Half-Life (Hours) | ESRD Half-Life (Hours) | Plasma Protein Binding (%) | Volume of Distribution (L/kg) | Dialytic Plasma Clearance (ml/min) | % Dialyzed |
---|---|---|---|---|---|---|---|
423 | 4-10 | 2.5-5.4 | 4-6 | 98 | 0.45 | N/A | 0 (high flux) |
References:
- Aronoff GR, Bennett WM, Berns JS, Brier ME, Kasbekar N, Mueller BA, et al. Drug Prescribing in Renal Failure. Philadelphia: American College of Physicians;2007.
- DrugBank [Online]. 2012 Apr 12 [cited 2012 May 6]; Available from: URL: http://www.drugbank.ca/drugs/DB00678
- Inrig J. Antihypertensive agents in hemodialysis patients: a current perspective. Seminars in dialysis. 2010;23(3):290-7.
- Sica D, Halstenson C, Gehr T, Keane W. Pharmacokinetics and blood pressure response of losartan in end-stage renal disease. Clinical pharmacokinetics. 2000;38(6):519-26.
- Toto R, Shultz P, Raij L, et al. Efficacy and Tolerability of Losartan in Hypertensive Patients With Renal Impairment. Hypertension. 1998;31:684-691.